Want to see ARZTY full AI Analyst Report?
ARZTY Stock Chart & Stats
$5.16
$0.00(0.00%)
At close: 4:00 PM EDT
$5.16
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$4.97 - $9.24
Previous CloseN/A
Volume30.00
Average Volume (3M)63.00
Market Cap
$1.23B
Enterprise Value$2.63K
Total Cash (Recent Filing)$74.37M
Total Debt (Recent Filing)$863.44M
Price to Earnings (P/E)10.3
Beta0.90
Next Earnings
Mar 08, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.42
Shares Outstanding248,276,440
10 Day Avg. Volume169
30 Day Avg. Volume63
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.34
Price to Sales (P/S)0.61
P/FCF Ratio7.84
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Profitability And Cash GenerationThe turnaround has produced sustained profitability and meaningful cash generation after earlier losses. This improves funding for reinvestment and debt service, giving Aryzta a stronger operating base even though cash conversion is not consistently improving.
Balance-Sheet RepairDebt reduction, lower leverage and a higher equity base improve financial resilience. Continued balance-sheet repair can reduce financing risk and create greater flexibility for investment, operational initiatives and potential shareholder distributions over the medium term.
Cost Savings And InnovationThe savings program has moved into delivery, with production coverage and quantified reductions already identified. Combined with a high innovation share supporting premiumization, these initiatives offer a durable route to better efficiency and mix.
Bears Say
Weak Organic GrowthNegative organic growth indicates that volume and mix are not yet providing dependable expansion. Persistent weakness would limit operating leverage, reduce the benefits of scale and make the recovery more dependent on acquisitions, pricing or cost actions.
Margin PressureLower EBITDA margins show that weak demand and cost pressures are reducing profitability despite procurement savings. Labor, energy and commodity effects could remain a structural challenge, while one-time program costs increase uncertainty around the pace of recovery.
Elevated LeverageAlthough leverage is improving, the more debt-heavy balance sheet still constrains financial flexibility. Elevated obligations can absorb cash that might otherwise fund growth or returns and leave the company more exposed to weaker earnings or refinancing pressure.
Aryzta ADR News
ARZTY FAQ
What was Aryzta ADR’s price range in the past 12 months?
Aryzta ADR lowest stock price was $4.97 and its highest was $9.24 in the past 12 months.
What is Aryzta ADR’s market cap?
Aryzta ADR’s market cap is $1.23B.
When is Aryzta ADR’s upcoming earnings report date?
Aryzta ADR’s upcoming earnings report date is Mar 08, 2027 which is in 184 days.
How were Aryzta ADR’s earnings last quarter?
Aryzta ADR released its earnings results on Aug 10, 2026. The company reported $0.212 earnings per share for the quarter.
Is Aryzta ADR overvalued?
According to Wall Street analysts Aryzta ADR’s price is currently Overvalued.
Does Aryzta ADR pay dividends?
Aryzta ADR pays a Notavailable dividend of $17.355 which represents an annual dividend yield of N/A. See more information on Aryzta ADR dividends here
What is Aryzta ADR’s EPS estimate?
Aryzta ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aryzta ADR have?
Aryzta ADR has 248,276,440 shares outstanding.
What happened to Aryzta ADR’s price movement after its last earnings report?
Aryzta ADR reported an EPS of $0.212 in its last earnings report. Following the earnings report the stock price went down -7.975%.
Which hedge fund is a major shareholder of Aryzta ADR?
Currently, no hedge funds are holding shares in ARZTY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aryzta ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.86%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aryzta ADR
Based in Schlieren, Switzerland, ARYZTA AG, established in 1897, operates as a leading supplier of frozen bakery solutions for business-to-business clients. Its operations span Europe, Asia, Australia, and New Zealand. The company's comprehensive product line includes diverse baked items such as pastries, biscuits, doughnuts, muffins, various buns, artisan breads, sweet morning treats, and a range of savory products. Beyond manufacturing, ARYZTA also offers asset management services and food product distribution. The firm caters to a broad customer base, including major retailers, convenience stores, independent merchants, quick-service restaurants, and other food service providers. It sells its goods under several well-known brands, such as Hiestaud, Mette Munk, Pre Pain, Cuisine de France, Coup de Pates, La Brea, Oits Spunkmeyer, and Fornetti. ARYZTA maintains a significant global footprint with 26 bakeries strategically located across 27 different nations.
ARZTY Company Deck
ARZTY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: operational and financial fundamentals are stabilizing — with confirmed cost savings from Project Excellence, reduced net debt, improved financing costs, stable free cash flow and ROIC above WACC — but top-line weakness, notably a significant drag from Germany and a modest EBITDA margin decline, are material near-term concerns. Management expects margin recovery in H2, continued contribution from innovation and new facilities, and is reviewing strategic options for Germany. The positives on balance-sheet repair, cost actions and clear targets are balanced by meaningful demand challenges and execution/strategic risk in Europe.View all ARZTY earnings summaries